Here, we report our experience in treating a periampullary carcinoma patient with high PD-L1 expression, high tumor mutation burden (TMB-H) and high microsatellite instability (MSI-H), who received a combination of Tislelizumab and chemotherapy. This evidence concerns the gene CD274 and neoplasm.